 |
1 Disease |  |
67 Trials |
|
67 Trials |  |
1555 News |  |
| 12345678910111213...3940» |
- | Libtayo (cemiplimab-rwlc) / Regeneron, Sarclisa (isatuximab-irfc) / Sanofi
Journal, PD(L)-1 Biomarker, IO biomarker: Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma. (Pubmed Central) - Mar 12, 2025
P2
The combination of isatuximab and cemiplimab demonstrated sustained antitumor activity and a manageable safety profile in R/R ENKTL. This phase II trial is registered at www.clinicaltrials.gov as #NCT04763616.
- Libtayo (cemiplimab-rwlc) / Regeneron, Aphexda (motixafortide) / BioLineRx, Ayrmid
Trial completion date, Trial primary completion date, Checkpoint inhibition: Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma (clinicaltrials.gov) - Mar 11, 2025
P2, N=10, Recruiting, Sponsor: Gulam Manji
This phase II trial is registered at www.clinicaltrials.gov as #NCT04763616. Trial completion date: Aug 2025 --> Aug 2028 | Trial primary completion date: Jul 2025 --> Jun 2028
- || Review, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Angiosarcoma: Role of Immunotherapy. (Pubmed Central) - Mar 9, 2025
Trial completion date: Aug 2025 --> Aug 2028 | Trial primary completion date: Jul 2025 --> Jun 2028 Single-agent ICI therapy, such as cemiplimab (ORR 27.8%), has shown responses primarily in UV- and radiation-associated angiosarcomas, likely due to their higher tumor mutation burden (TMB), while dual ICI therapy (SWOG S1609, ORR 25%) suggests potential benefit but remains limited in cutaneous disease...The Alliance A091902 first-line trial (paclitaxel?
- Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
Fianlimab + cemiplimab in patients with advanced melanoma: Subgroup analyses by blinded independent central review (BICR) (A-310) (M2 150 seats / Level -1) - Mar 8, 2025 - Abstract #EADOWCM2025EADO_WCM_469;
- Libtayo (cemiplimab-rwlc) / Regeneron
Neoadjuvant Cemiplimab for Stage II-IV Cutaneous Squamous Cell Carcinoma: 2-Year Follow-up and Biomarker Analyses (A-332) (M2 150 seats/Level -1) - Mar 8, 2025 - Abstract #EADOWCM2025EADO_WCM_419;
- || Libtayo (cemiplimab-rwlc) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
Review, Journal, Checkpoint inhibition, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Immune checkpoint inhibitors for children with xeroderma pigmentosum and advanced cutaneous squamous cell carcinoma: A case presentation and brief review. (Pubmed Central) - Mar 7, 2025
Following a tumor board recommendation, systemic immunotherapy with cemiplimab was initiated...Incidence and nature of adverse events in XP patients were comparable to those observed in the general population. In line with the previously reported ICI-treated XP children, the present case confirms that anti-PD-1 inhibitors are highly effective in children with XP and advanced cSCC.
- ||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open: Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC (clinicaltrials.gov) - Mar 7, 2025
P2, N=112, Recruiting, Sponsor: Weill Medical College of Cornell University
In line with the previously reported ICI-treated XP children, the present case confirms that anti-PD-1 inhibitors are highly effective in children with XP and advanced cSCC. Not yet recruiting --> Recruiting
- |||| fianlimab/cemiplimab FDC (REGN3767/REGN2810 FDC) / Regeneron
New P2 trial: TRIPL: Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 7, 2025
P2, N=76, Not yet recruiting, Sponsor: Albert Einstein College of Medicine
- | Libtayo (cemiplimab-rwlc) / Regeneron
New P2 trial: Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer (clinicaltrials.gov) - Mar 6, 2025
P2, N=11, Not yet recruiting, Sponsor: City of Hope Medical Center
- || Libtayo (cemiplimab-rwlc) / Regeneron, Praluent (alirocumab) / Sanofi, Regeneron
Trial completion date, Trial primary completion date: TOP 2301: Neoadjuvant Chemo for NSCLC (clinicaltrials.gov) - Mar 5, 2025
P2, N=126, Recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting Trial completion date: Aug 2028 --> Oct 2029 | Trial primary completion date: Aug 2026 --> Oct 2027
- | Jakafi (ruxolitinib) / Incyte, Libtayo (cemiplimab-rwlc) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
Journal: Aggressive cutaneous squamous cell carcinoma in a patient on Janus-kinase inhibitor therapy. (Pubmed Central) - Mar 3, 2025
Trial completion date: Aug 2028 --> Oct 2029 | Trial primary completion date: Aug 2026 --> Oct 2027 No abstract available
- || Libtayo (cemiplimab-rwlc) / Regeneron, Erbitux (cetuximab) / Eli Lilly
New P2 trial: Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC (clinicaltrials.gov) - Mar 3, 2025
P2, N=21, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- ||| REGN5093-M114 / Regeneron
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer (clinicaltrials.gov) - Feb 28, 2025
P1/2, N=30, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
No abstract available Recruiting --> Active, not recruiting | N=237 --> 30 | Trial completion date: Feb 2030 --> Oct 2027 | Trial primary completion date: Feb 2030 --> Aug 2027
- | Libtayo (cemiplimab-rwlc) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
Journal: Immunotherapy for orbital squamous cell carcinoma. (Pubmed Central) - Feb 27, 2025
Two (66%) patients that had tissue analysis following immunotherapy showed complete pathologic response. Our findings support the emerging role of immunotherapy in the management of invasive orbital squamous cell carcinoma.
- |||| Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
New P2 trial: A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment (clinicaltrials.gov) - Feb 26, 2025
P2, N=98, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- ||| REGN6569 / Regeneron, Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial termination: Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - Feb 24, 2025
P1, N=38, Terminated, Sponsor: Regeneron Pharmaceuticals
Our findings support the emerging role of immunotherapy in the management of invasive orbital squamous cell carcinoma. Trial completion date: Sep 2025 --> Feb 2025 | Active, not recruiting --> Terminated; Sponsor Decision
- || BDC-3042 / Bolt Biotherap
Enrollment closed: BBI-20233042: Study of BDC-3042 As Single Agent and in Combination with Cemiplimab in Patients with Advanced Malignancies (clinicaltrials.gov) - Feb 24, 2025
P1/2, N=147, Active, not recruiting, Sponsor: Bolt Biotherapeutics, Inc.
Trial completion date: Sep 2025 --> Feb 2025 | Active, not recruiting --> Terminated; Sponsor Decision Recruiting --> Active, not recruiting
- Libtayo (cemiplimab-rwlc) / Regeneron
Systematic Review and Meta-Analysis on Efficacy and Safety of Cemiplimab in Locally Advanced and Metastatic Squamous Cell Carcinoma () - Feb 21, 2025 - Abstract #AAD2025AAD_3182;
Recruiting --> Active, not recruiting Our findings indicate that cemiplimab may be an effective and safe treatment for advanced cSSC.
- A Retrospective Cohort Study: The Safety and Feasibility of Infusing Biological Medications in a Dermatology Practice () - Feb 21, 2025 - Abstract #AAD2025AAD_2841;
Pre-medicating patients mitigated most reactions, with manageable symptoms like headache and fatigue. Our findings demonstrate that intravenous (IV) infusion medications can be safely administered within the dermatology office setting, providing an all-inclusive and convenient option for patient care in the dermatology practice.
- Blistering disease development following immune checkpoint inhibitor immunotherapy: An analysis of the FDA adverse event reporting system database () - Feb 21, 2025 - Abstract #AAD2025AAD_2701;
Similar to other studies, we find a higher rate of BP in male patients and older individuals, yet this is among the first studies to describe a lower risk in pemphigus, possibly due to higher stimulation of T-cell cross-reactivity with BP vs pemphigus self-antigens peripherally. Identification of riskier causative agents may aid in treatment selection, especially in patients with previous history of AIBD or genetic susceptibility.
- Herceptin (trastuzumab) / Roche
Trastuzumab: a potential therapy for unresectable Stage IV cutaneous squamous cell carcinoma () - Feb 21, 2025 - Abstract #AAD2025AAD_2409;
Identification of riskier causative agents may aid in treatment selection, especially in patients with previous history of AIBD or genetic susceptibility. Cutaneous squamous cell carcinomas (SCC) are common cutaneous cancers with excellent prognosis.1 3-5% of SCCs develop metastasis which are often complicated by poor therapeutic response and recurrence.1,2 Epidermal growth factor receptors, HER2, HER3, and HER4, have been implicated in SCCs, however, its therapeutic potential have yet to be delineated.3
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial initiation date: Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer (clinicaltrials.gov) - Feb 21, 2025
P3, N=420, Recruiting, Sponsor: National Cancer Institute (NCI)
Cutaneous squamous cell carcinomas (SCC) are common cutaneous cancers with excellent prognosis.1 3-5% of SCCs develop metastasis which are often complicated by poor therapeutic response and recurrence.1,2 Epidermal growth factor receptors, HER2, HER3, and HER4, have been implicated in SCCs, however, its therapeutic potential have yet to be delineated.3 Initiation date: Sep 2025 --> Feb 2025
- | Libtayo (cemiplimab-rwlc) / Regeneron
New P2 trial: Immunotherapy in Perineural Spread of Cutaneous Squamous Cell Carcinoma - IPERCS (EUDRACT) - Feb 21, 2025
P2, N=22, Not yet recruiting, Sponsor: Metro South Hospital and Health Services
- | New P3 trial: OliGRAIL: First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients. (clinicaltrials.gov) - Feb 20, 2025
P3, N=124, Not yet recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- || Libtayo (cemiplimab-rwlc) / Regeneron
Review, Journal: Recent advances in immunotherapy for cervical cancer. (Pubmed Central) - Feb 20, 2025
Clinical trials involving immune checkpoint inhibitors are now being conducted following a phase 3 trial with cemiplimab, an ICI, which demonstrated a significant improvement in prognosis in advanced or metastatic cervical cancer patients...Ongoing trials will continue to illuminate the optimal strategies for combining these therapies and addressing challenges associated with immune checkpoint failure in cervical cancer. Herein, we conducted a review of articles related to immunotherapy for cervical cancer and describe current treatment strategies for cervical cancer via immunotherapy.
- | Libtayo (cemiplimab-rwlc) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
Journal: Severe hypersensitivity reactions to 2 immunotherapy agents in a patient with cutaneous squamous cell carcinoma. (Pubmed Central) - Feb 20, 2025
Herein, we conducted a review of articles related to immunotherapy for cervical cancer and describe current treatment strategies for cervical cancer via immunotherapy. A patient with metastatic cutaneous squamous cell carcinoma developed a severe hypersensitivity reaction to pembrolizumab and subsequently to cemiplimab, despite premedication.
- ||| nezastomig (REGN5678) / Regeneron, Libtayo (cemiplimab-rwlc) / Regeneron
New P1 trial: A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC (clinicaltrials.gov) - Feb 15, 2025
P1, N=60, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Libtayo (cemiplimab-rwlc) / Regeneron, Erivedge (vismodegib) / Roche
Journal: Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy. (Pubmed Central) - Feb 14, 2025
A wide excision demonstrated a pathologic complete response. Further evaluation of cemiplimab and hedgehog inhibitor combination therapy in la BCC appears warranted.
- | GRWD5769 / Grey Wolf Therap
Phase classification, Enrollment change: A clinical trial to determine the safety and tolerability of GRWD5769 in combination with anticancer treatments in patients with solid malignancies. (EUDRACT) - Feb 13, 2025
P1/2, N=168, Recruiting, Sponsor: Grey Wolf Therapeutics Pty Ltd
Further evaluation of cemiplimab and hedgehog inhibitor combination therapy in la BCC appears warranted. Phase classification: P1 --> P1/2 | N=36 --> 168
- | Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
Trial initiation date: Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT) (clinicaltrials.gov) - Feb 12, 2025
P2, N=36, Not yet recruiting, Sponsor: Columbia University
Phase classification: P1 --> P1/2 | N=36 --> 168 Initiation date: Nov 2024 --> Jun 2025
- ||| Akalux (cetuximab sarotalocan) / Rakuten Medical
Enrollment change, Trial completion date, Trial primary completion date: An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination with Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors (clinicaltrials.gov) - Feb 12, 2025
P1/2, N=23, Active, not recruiting, Sponsor: Rakuten Medical, Inc.
Initiation date: Nov 2024 --> Jun 2025 N=74 --> 23 | Trial completion date: Jun 2025 --> Jun 2027 | Trial primary completion date: Jun 2024 --> Jun 2026
- | Libtayo (cemiplimab-rwlc) / Regeneron, fianlimab (REGN3767) / Regeneron
Enrollment open, Trial completion date, Trial primary completion date: A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Feb 12, 2025
P2, N=10, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=74 --> 23 | Trial completion date: Jun 2025 --> Jun 2027 | Trial primary completion date: Jun 2024 --> Jun 2026 Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Feb 2028 | Trial primary completion date: Dec 2026 --> Feb 2028
- | Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment closed, Trial completion date, Trial primary completion date: Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (clinicaltrials.gov) - Feb 11, 2025
P2, N=36, Active, not recruiting, Sponsor: Medical College of Wisconsin
Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Feb 2028 | Trial primary completion date: Dec 2026 --> Feb 2028 Recruiting --> Active, not recruiting | Trial completion date: Jan 2026 --> Aug 2025 | Trial primary completion date: Jan 2025 --> Jul 2025
- | Libtayo (cemiplimab-rwlc) / Regeneron, tirbanibulin oral (KX2-391 oral) / Athenex
Journal: From basic to clinical and therapeutic insights: news on actinic keratosis and skin squamous cell carcinoma. (Pubmed Central) - Feb 7, 2025
In treatment, immune checkpoint inhibitors have shown good survival outcomes for advanced SCC. Research continues in the neoadjuvant setting and among transplanted patients, with encouraging preliminary results.
- | Retrospective data, Journal: Comparative efficacy and safety of first?line PD?1/PD?L1 inhibitors in immunotherapy for non?small cell lung cancer: (Pubmed Central) - Feb 7, 2025
While cemiplimab and tislelizumab had the highest probabilities of improved PFS, no significant differences were observed across all PD-1/PD-L1 inhibitors...However, the combination of PD-1/PD-L1 inhibitors with chemotherapy increased the risk of severe adverse events. Further research is needed to optimize treatment strategies.
- | Libtayo (cemiplimab-rwlc) / Regeneron
Journal: CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma. (Pubmed Central) - Feb 6, 2025
P=N/A
Outcome measures of the study include response to treatment, quality of life, safety, treatment patterns, patient experience, and survival. This study could provide a more complete characterization of this patient population and fill knowledge gaps related to real-world treatment utilization and patient outcomes.Clinical Trial registration: NCT03836105.
- || Libtayo (cemiplimab-rwlc) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Journal, HEOR, Cost-effectiveness: Cost-effectiveness of cemiplimab plus chemotherapy vs pembrolizumab plus chemotherapy as first-line treatment for advanced non-small cell lung cancer. (Pubmed Central) - Feb 6, 2025
In subgroup analyses, CCT remained a dominant alternative to PCT for patients with PD-L1?levels of at least 50% and 1%-49%. This cost-effectiveness analysis suggests that CCT is a dominant first-line treatment option for aNSCLC with PD-L1?levels of at least 1% compared with PCT.
- || Libtayo (cemiplimab-rwlc) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
Review, Journal: Pembrolizumab for the Treatment of Locally Advanced Cutaneous Squamous Cell Carcinoma: Patient Selection and Special Considerations. (Pubmed Central) - Feb 6, 2025
This cost-effectiveness analysis suggests that CCT is a dominant first-line treatment option for aNSCLC with PD-L1?levels of at least 1% compared with PCT. Recently, ICIs such as pembrolizumab and cemiplimab have emerged as effective alternatives for treating advanced
- ||| Retrospective data, Review, Journal, Adverse events, Checkpoint inhibition: Cardiotoxicity associated with immune checkpoint inhibitors: Systematic Review and Meta-analysis. (Pubmed Central) - Feb 5, 2025
This study proved that the recognition of frequency and severity of all grade cardiotoxicity associated with ICIs is still underestimated. Thus, a systematic cardiological screening becomes necessary, in order to intercept the potential cardiological complications beforehand and optimize the outcomes of the respective treatment with PD-1, PD-L1 and CTLA-4 inhibitors.
- ||| HST-1011 / HotSpot Therap
Enrollment closed, Enrollment change, Monotherapy: SOLAR1: A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody (clinicaltrials.gov) - Feb 4, 2025
P1/2, N=77, Active, not recruiting, Sponsor: HotSpot Therapeutics, Inc
Thus, a systematic cardiological screening becomes necessary, in order to intercept the potential cardiological complications beforehand and optimize the outcomes of the respective treatment with PD-1, PD-L1 and CTLA-4 inhibitors. Recruiting --> Active, not recruiting | N=203 --> 77
- ||| Journal, Adverse events, Checkpoint inhibition: Self-Organizing Map-Based Assessment of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors. (Pubmed Central) - Feb 4, 2025
The eight ICIs were divided into four groups based on the reported rates of type 1 diabetes mellitus and hematological disorders. Conclusion Our findings provide a reference for healthcare providers to predict irAE characteristics induced by ICIs in patients, thereby facilitating effective cancer treatment.
- | Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date: CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) - Feb 4, 2025
P1/2, N=12, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Conclusion Our findings provide a reference for healthcare providers to predict irAE characteristics induced by ICIs in patients, thereby facilitating effective cancer treatment. Trial completion date: Jan 2025 --> Jan 2026
- | Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open, IO biomarker: ICARS: Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC (clinicaltrials.gov) - Feb 3, 2025
P2, N=136, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial completion date: Jan 2025 --> Jan 2026 Not yet recruiting --> Recruiting
- ||| Libtayo (cemiplimab-rwlc) / Regeneron
P3 data, Journal, PD(L)-1 Biomarker, IO biomarker: Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial. (Pubmed Central) - Feb 1, 2025
The safety profile was consistent with published data; incidences of adverse events were similar between cemiplimab and chemotherapy groups. These results support the use of second-line cemiplimab for patients with recurrent cervical cancer.
- | Libtayo (cemiplimab-rwlc) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
New trial, IO biomarker: IMMUNO_ASSAY: Detection of Circulating Therapeutic Monoclonal Antibodies in Biological Samples of Gynecological Cancer Patients. (clinicaltrials.gov) - Jan 28, 2025
P=N/A, N=12, Not yet recruiting, Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- || tuvusertib (M1774) / EMD Serono
Trial completion date, Trial primary completion date: Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) (clinicaltrials.gov) - Jan 28, 2025
P1/2, N=61, Active, not recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
These results support the use of second-line cemiplimab for patients with recurrent cervical cancer. Trial completion date: Mar 2025 --> Feb 2026 | Trial primary completion date: Jun 2024 --> May 2025
- Libtayo (cemiplimab-rwlc) / Regeneron
BILATERAL PTOSIS AND ELEVATED TROPONIN IN SQUAMOUS CELL CARCINOMA TREATMENT: A RARE CASE OF CEMIPLIMAB ADVERSE EFFECTS - Benjamin Szumowski (Board 266; South Hall) - Jan 27, 2025 - Abstract #ACC2025ACC_886;
- || isatuximab subcutaneous (SAR650984 SC) / Sanofi
Enrollment closed: International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab (clinicaltrials.gov) - Jan 23, 2025
P2, N=70, Active, not recruiting, Sponsor: Sanofi
Trial completion date: Mar 2025 --> Feb 2026 | Trial primary completion date: Jun 2024 --> May 2025 Recruiting --> Active, not recruiting
- | Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment closed: Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jan 23, 2025
P2, N=46, Active, not recruiting, Sponsor: Marcelo Bonomi
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open, Trial completion date, Trial primary completion date: Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 22, 2025
P3, N=369, Recruiting, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Jun 2029 --> May 2030 | Trial primary completion date: Jun 2029 --> May 2030